| Dr Robert Michael Buchsbaum, MD | |
|
4881 Sugar Maple Dr, 88mdg/sgqc, Wright Patterson Afb, OH 45433-5546 | |
| (937) 257-9344 | |
| Not Available |
| Full Name | Dr Robert Michael Buchsbaum |
|---|---|
| Gender | Male |
| Speciality | Pathology - Anatomic Pathology & Clinical Pathology |
| Location | 4881 Sugar Maple Dr, Wright Patterson Afb, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326039777 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZB0001X | Pathology - Blood Banking & Transfusion Medicine | H5849 (Texas) | Primary |
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | H5849 (Texas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert Michael Buchsbaum, MD 2859 Homeway Dr, Dayton, OH 45434-5706 Ph: () - | Dr Robert Michael Buchsbaum, MD 4881 Sugar Maple Dr, 88mdg/sgqc, Wright Patterson Afb, OH 45433-5546 Ph: (937) 257-9344 |
News Archive
Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced interim data from a 12-week phase IIb clinical trial of IDX184, the Company's lead product candidate for the treatment of hepatitis C virus (HCV) infection.
The Trudeau Institute has announced it is the recipient of a sub-contract for a translational research grant from the National Institutes of Health.
A computerized bilingual decision aid - placed in safety-net clinics and health fairs - can prompt Hispanic and other smokers to set a quit date and choose effective treatments.
RedHill Biopharma Ltd. (NASDAQ; RDHL) (TASE: RDHL) ("RedHill" or the "Company"), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that it has initiated a randomized, double-blind, 2-arm parallel group Phase II clinical study in the U.S. evaluating the safety and efficacy of BEKINDA™ 12 mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
› Verified 3 days ago
Dr. Emily May Miller, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 4881 Sugar Maple Dr, 88mdg/sgqc, Wright Patterson Afb, OH 45433 Phone: 937-257-9392 | |
Dr. Bradley J. Lachey, M.D. Pathology Medicare: Medicare Enrolled Practice Location: 4881 Sugar Maple Dr, Wright Patterson Afb, OH 45433 Phone: 937-257-1489 | |
Dr. An Zhu, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 4881 Sugar Maple Dr, 88 Mdg/sghj, Wright Patterson Afb, OH 45433 Phone: 937-257-9394 |